Bevatas 100 mg contains Bevacizumab, a monoclonal antibody designed to block the growth of new blood vessels (a process called angiogenesis) that tumors need to grow and spread.
It is administered intravenously under medical supervision and is commonly used in various advanced or metastatic cancers.
By “starving” the tumor of its blood supply, bevacizumab helps slow cancer progression and, in many cases, improves survival when used alongside chemotherapy.

Mechanism of Action

Bevacizumab specifically targets and binds to vascular endothelial growth factor A (VEGF-A) — a key protein that stimulates the formation of blood vessels.

• By neutralizing VEGF-A, bevacizumab inhibits angiogenesis, the formation of new blood vessels.

• This cuts off the tumor’s supply of oxygen and nutrients, slowing its growth and ability to spread.

• It also helps normalize abnormal tumor blood vessels, improving the delivery of other chemotherapy agents to the tumor site.

  Uses / Indications

  Bevatas (Bevacizumab) is used in the treatment of several cancers, often in combination with other chemotherapies, including:

  1. Metastatic Colorectal Cancer

  2. Non-Small Cell Lung Cancer (NSCLC) — non-squamous type

  3. Recurrent Glioblastoma (brain cancer)

  4. Metastatic Renal Cell Carcinoma (kidney cancer)

  5. Cervical Cancer and Ovarian Cancer (advanced/recurrent)

  6. Hepatocellular Carcinoma (liver cancer) – in combination with atezolizumab